OTCMKTS:BVNRY Bavarian Nordic (BVNRY) Stock Price, News & Analysis $8.81 -0.02 (-0.17%) As of 01:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Bavarian Nordic Stock (OTCMKTS:BVNRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bavarian Nordic alerts:Sign Up Key Stats Today's Range$8.81▼$8.8350-Day Range$7.36▼$9.5352-Week Range$6.60▼$14.60Volume1,256 shsAverage Volume7,164 shsMarket Capitalization$2.08 billionP/E Ratio11.01Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. Read More… Receive BVNRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bavarian Nordic and its competitors with MarketBeat's FREE daily newsletter. Email Address BVNRY Stock News HeadlinesBavarian Nordic A/S ADR (BVNRY) Stock Price Today - WSJJune 28 at 4:37 PM | wsj.comBavarian Nordic A/S: Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 MillionJune 18, 2025 | finanznachrichten.deA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 30 at 2:00 AM | Porter & Company (Ad)Bavarian Nordic sells its Priority Review Voucher for $160MJune 18, 2025 | seekingalpha.comBavarian Nordic A/S: Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in ChildrenJune 12, 2025 | finanznachrichten.deBavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in ChildrenJune 12, 2025 | finance.yahoo.comUndiscovered European Gems Including 3 Promising Small CapsMay 12, 2025 | finance.yahoo.comBavarian Nordic AS (BVNKF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...May 12, 2025 | gurufocus.comSee More Headlines BVNRY Stock Analysis - Frequently Asked Questions How have BVNRY shares performed this year? Bavarian Nordic's stock was trading at $8.7060 at the beginning of 2025. Since then, BVNRY stock has increased by 1.2% and is now trading at $8.81. View the best growth stocks for 2025 here. How were Bavarian Nordic's earnings last quarter? Bavarian Nordic (OTCMKTS:BVNRY) released its quarterly earnings data on Friday, May, 9th. The company reported $0.13 earnings per share (EPS) for the quarter. The business earned $189.89 million during the quarter. Bavarian Nordic had a trailing twelve-month return on equity of 11.89% and a net margin of 21.11%. How do I buy shares of Bavarian Nordic? Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/09/2025Today6/30/2025Next Earnings (Estimated)8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:BVNRY CIKN/A Webwww.bavarian-nordic.com Phone(453) 326-8383Fax45-3326-8380Employees1,611Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.80 Trailing P/E Ratio11.01 Forward P/E Ratio13.15 P/E GrowthN/ANet Income$143.26 million Net Margins21.11% Pretax Margin21.18% Return on Equity11.89% Return on Assets9.32% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio1.44 Sales & Book Value Annual Sales$829.12 million Price / Sales2.51 Cash Flow$1.01 per share Price / Cash Flow8.71 Book Value$6.99 per share Price / Book1.26Miscellaneous Outstanding Shares236,570,000Free FloatN/AMarket Cap$2.08 billion OptionableNot Optionable Beta1.36 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:BVNRY) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bavarian Nordic Please log in to your account or sign up in order to add this asset to your watchlist. Share Bavarian Nordic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.